GET DAILY SIGNALSBio-Rad Laboratories (BIO) vs FactSet Research Systems (FDS): Momentum in Life Sciences Meets Steady Growth in Financial Data
Key Takeaways
- BIO has rallied sharply in recent weeks on digital PCR momentum and steady diagnostics demand, yet weak life science spending and a premium valuation temper the move.
- FDS has delivered accelerating organic growth and record subscription value, powered by rising demand for AI-ready financial data, but faces margin compression.
- The two companies operate in entirely different sectors, making this a contrast between a cyclical life sciences recovery story and a durable, recurring-revenue financial data franchise.
- BIO offers higher upside potential but carries execution and geopolitical risk; FDS offers steadier cash flow and a long dividend-growth track record.
- Relative performance and trend consistency currently diverge, with each stock presenting a distinct risk-reward profile for different investor styles.
Setting the Context
Investors often weigh growth potential against stability when comparing businesses with very different models. Bio-Rad Laboratories (BIO), a leader in life science research tools and clinical diagnostics, and FactSet Research Systems (FDS), which delivers financial data, analytics, and workflow software, sit in separate corners of the market. This comparison looks at their recent performance, growth drivers, and positioning. It can help traders focused on momentum as well as longer-term investors evaluating recurring revenue quality, sector exposure, and risk. I also checked this using Tickeron’s AI Screener to see how the stocks compare within their industries.
Bio-Rad Laboratories Overview and Recent Moves
Bio-Rad Laboratories develops life science research tools and clinical diagnostics products across two main segments. The stock has advanced roughly 19% over the past month, outpacing both its industry and the broader market. Much of the strength stems from digital PCR momentum, where instrument revenue grew more than 20% year over year thanks to competitive wins and the Stilla portfolio integration.
Clinical Diagnostics makes up the bulk of revenue and has offered a more stable recurring base, with solid contributions from quality controls, diabetes products, and blood typing. Still, Life Science demand stays soft due to constrained academic funding, and geopolitical issues in the Middle East have affected diagnostics revenue. A large quarterly net loss tied to equity holdings has clouded underlying trends. Shares trade at a notable forward earnings premium to peers, so much depends on cost-saving execution and further digital PCR adoption.
FactSet Research Systems Overview and Recent Moves
FactSet Research Systems supplies integrated financial data, analytics, and workflow solutions on a high-margin subscription basis to asset managers, banks, wealth advisors, and others. Fiscal 2026 results showed revenue up 6.7% to about $2.48 billion, extending a 47-year streak of annual increases, along with a 30th straight year of adjusted EPS growth. Organic Annual Subscription Value rose 7%.
Adoption of AI-enabled products has supported sentiment, with a meaningful portion of new subscription growth linked to AI SKUs and expanding use of model context protocol data. Wealth management and dealmaker areas have been particularly strong. Adjusted operating margins have faced pressure from higher compensation and technology spending, and the stock eased modestly from recent highs after a solid advance. FactSet’s 27 consecutive years of dividend increases and active buyback program highlight its cash-generation strength, though margin trends remain worth watching.
Head-to-Head Comparison
The fundamental difference lies in business structure. Bio-Rad is a cyclical, innovation-focused life sciences firm whose growth relies on instrument placements, consumable pull-through, and research funding cycles. Its recent momentum ties to digital PCR and cost efforts, while risks include soft academic demand, regional disruptions, and an elevated valuation. FactSet, on the other hand, runs a sticky recurring-revenue model with high retention, consistent cash flow, and steady capital returns, though growth is more moderate and margins face pressure from technology and compensation costs.
On momentum, BIO delivered the sharper short-term move, while FDS showed steadier acceleration followed by a pullback. Sector exposure differs markedly: BIO links to healthcare and life sciences budgets, whereas FDS reflects financial services spending and AI adoption. In risk terms, BIO carries higher upside potential but less predictable near-term earnings, while FDS provides more visible recurring economics with moderate growth.
Using AI Tools for Additional Perspective
One resource I turn to for systematic views is Tickeron’s AI Trading Bots. It lets users explore automated strategies across many tickers and timeframes, which can help match different risk-reward profiles like those of BIO and FDS to individual objectives without relying solely on manual analysis.
AI Verdict on the Pair
Based on the observable factors, Tickeron’s AI would likely lean toward FDS for trend consistency and stability. Its accelerating organic subscription growth, record ASV, high retention, and durable cash flow point to a steadier profile than BIO’s sharper but more volatile rally, which hinges heavily on digital PCR adoption and cost execution amid softer end markets. Momentum signals could still highlight BIO for its stronger recent price move. The outcome depends on the specific timeframe and weighting an AI model applies, so neither view should be seen as definitive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of life science research products and clinical diagnostics
Industry MedicalNursingServices
Advertisement